Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline

On June 4, Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at $130. His optimistic view reflects confidence in the company’s pipeline momentum and execution on upcoming launches.

Yee points to Gilead’s lenacapavir PrEP (HIV prevention) therapy as a key near-term catalyst. Gilead expects FDA approval and has prepared a commercial rollout. If approved, lenacapavir could drive revenue growth, supported by high patient adherence and favorable reimbursement terms.

Jefferies Maintains Buy on Gilead (GILD) Citing Robust Pipeline

A close-up of a hand holding a vial of biopharmaceutical drugs ready to be administered.

Gilead is also working on a once-yearly injectable version of lenacapavir, which has shown positive results in Phase II trials and is now advancing to Phase III. This version aims to improve HIV prevention by making treatment more convenient and addressing long-term adherence challenges.

Yee also highlights that beyond HIV, Gilead continues to build momentum in oncology. Its Trodelvy therapy is being explored for use in the first-line treatment of triple-negative breast cancer (1L TNBC), and the company is progressing with its BCMA CAR-T therapy for multiple myeloma, both of which are considered crucial long-term growth drivers.

Gilead Sciences Inc. (NASDAQ:GILD) is a U.S.-based biopharmaceutical company that specializes in discovering, developing, and commercializing innovative medicines, primarily focusing on antiviral therapies for diseases such as HIV/AIDS, hepatitis B and C, and COVID-19.

While we acknowledge the potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.